AURA (Aura Biosciences) Tariff Resilience Score: 7/10 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AURA Aura Biosciences Inc AURA
34 GF Score
Price $6.97
! 3 Warning Signs
View Full Analysis

What is Aura Biosciences Tariff Resilience Score?

Aura Biosciences AURA +1.60% 34 Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus rates AURA with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,370 Biotechnology companies, Aura Biosciences ranks better than 90.36% on this metric.

Aura Biosciences has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Aura Biosciences has Aura Biosciences primarily operates in the biotech sector with limited exposure to tariffs. Its supply chain is less dependent on international trade, and its products are often exempt from tariffs due to their medical nature. However, any changes in tariffs on raw materials could impact costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Aura Biosciences might have Highly Resilient.

Aura Biosciences  (NAS:AURA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Aura Biosciences Tariff Resilience Score Related Terms

AURA vs NVCT, CADL, OCS: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Aura Biosciences's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aura Biosciences Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's Tariff Resilience Score falls into.


AURA
34GF Score
Aura Biosciences Inc AURA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Aura Biosciences (AURA) has a Tariff Resilience Score of 7 as of Jul. 18, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Aura Biosciences ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Aura Biosciences' Tariff Resilience Score too high?
Aura Biosciences' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Aura Biosciences' value of 7 is 75% above this industry median. Based on the distribution chart, Aura Biosciences ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aura Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Aura Biosciences' Tariff Resilience Score compare to NVCT and CADL?
According to the Biotechnology industry distribution chart, Aura Biosciences ranks #132 out of 1370 companies for Tariff Resilience Score. This places Aura Biosciences in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Aura Biosciences' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aura Biosciences's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aura Biosciences's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aura Biosciences stock overvalued right now?
Aura Biosciences (AURA) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Aura Biosciences' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Aura Biosciences (AURA), the current Tariff Resilience Score is 7 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aura Biosciences Business Description

Address 80 Guest Street, Boston, MA, USA, 02135
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
34GF Score

Get the complete analysis for AURA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.97
Price